Influence of medical intervention on sympathetic activity in heart failure

de Milliano, P.A.R.

Citation for published version (APA):
Contents

I. Introduction 7

II. Heart failure, pathophysiology and compensatory mechanisms. 15

III. Sympathetic activation in heart failure. 25

IV. Beta-blockers in heart failure: hemodynamics, clinical effects and modes of action. 35

V. Increased myocardial 121I-metaiodobenzylguanidine uptake after enalapril treatment in patients with chronic heart failure.
   G. Aeroudt Somsen, Bob van Vlies, Paul A.R. de Milliano, Judocus J.J. Born,
   Eric A. van Royen, Erik Endert, Kong I. Lie.
   Heart 1996; 76:218-222

VI. Beneficial effects of metoprolol on myocardial sympathetic function.
   Evidence from a randomized, placebo controlled study in patients with congestive heart failure.
   Paul A.R. de Milliano, MD, Andre C. de Groot, MD, Jan G.P. Tijssen, MD, PhD,
   Berthe L.F. van Eck-Smit, MD, PhD, Pieter A. van Zwieten, MD, PhD, and
   Kong I. Lie, MD, PhD.
   American Heart Journal: in press.

VII. Relationship between cardiac MIBG uptake and hemodynamic, functional and neurohormonal parameters in patients with heart failure.
   Paul A.R. de Milliano, MD; Berthe L.F. van Eck-Smit, MD, PhD; Pieter A. van
   Zwieten, MD, PhD; Andre C. de Groot, MD; Jan G.P. Tijssen, MD, PhD; Kong
   I. Lie, MD, PhD.
   European Journal of Heart Failure 2001; 3:693-697

VIII. Cardiac 123I-MIBG imaging and clinical variables in risk stratification in patients
   with heart failure treated with β-blockers.
   Nuclear Medicine Communications: in press.
IX. Metoprolol-induced changes in myocardial $^{123}$I-Metaiodobenzylguanidine uptake in Parkinson’s disease.
Paul A.R. de Milliano, MD; Berthe L.F. van Eck-Smit, MD; Andre C. de Groot, MD; Kong I. Lie, MD, PhD.

X. General discussion and clinical implications.

XI. Summary
Samenvatting

Dankwoord

Curriculum Vitae